Product Description
Fomivirsen sodium is a 21-base phosphorothioate oligodeoxynucleotide complementary to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, and is a potent and selective antiviral agent for cytomegalovirus retinitis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11978144/)
Mechanisms of Action: mIR-1222 Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Isis|Alnylam
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis C
Phase 2: Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2015-004702-42 | P2 |
Completed |
Hepatitis C, Chronic |
2017-09-21 |
|
2016-002069-77 | P3 |
Completed |
Hepatitis C |
2017-09-14 |
|
2015-001535-21 | P2 |
Completed |
Hepatitis C, Chronic |
2017-01-18 |